VERV
Sign in
Verve Therapeutics, Inc.
Save
485.97M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
Similar securities
Based on sector and market capitalization
Report issue